Results 111 to 120 of about 22,201 (271)

Barriers and facilitators to detoxification from opioid substitution treatment: A mixed‐methods systematic review

Addiction, EarlyView.
Abstract Background and aims Despite the well‐documented benefits of opioid substitution treatment (OST) in treating opioid dependence (OD), many people diagnosed with OD desire to live a drug‐free life. The transition to abstinence involves detoxification: a gradual dose reduction of OST to zero milligrams.
Amy Bagshaw, Suleyman Shah, India Olchefske, Louise M. Paterson, Mike J. Crawford, Anne Lingford‐Hughes   +5 more
wiley   +1 more source

Long-Acting Injectable naltrexone for the Management of patients with Opioid Dependence

Substance Abuse: Research and Treatment, 2011
Opioid dependence is a condition with serious clinical ramifications. Treatment has focused on detoxification, agonist therapy with methadone or buprenorphine, or remission maintenance with the opioid antagonist, naltrexone.
Kimberly L. Kjome, F. Gerard Moeller
doaj   +1 more source

Patient-elected low-dose intravenous naloxone for rapid buprenorphine induction: a case report

Addiction Science & Clinical Practice
Background Buprenorphine is a common partial opioid agonist treatment for opioid use disorder (OUD). Despite its efficacy, major challenges to induction include the significant time consumption and the difficult requirement for patients to be in moderate
Pouya Azar, Jessica Machado, Jane J. Kim, James S. H. Wong, Mohammadali Nikoo, Victor W. Li   +5 more
doaj   +1 more source

Subst Abus [PDF]

Background:There has been a rise in opioid abuse and related injection drug use in the United States and treatment for opioid use disorders may be underutilized.

core  

Factors associated with the percentage of individuals who initiate and discontinue naltrexone as a relapse prevention pharmacotherapy in opioid use disorder: A systematic review, meta‐analysis and meta‐regression

Addiction, EarlyView.
Abstract Background and aims Naltrexone is a pharmacotherapeutic option for relapse prevention in opioid use disorder (OUD); however, studies highlight low rates of initiation and high rates of discontinuation as limiting its effectiveness. We aimed to (1) estimate the percentage of individuals with OUD who (having undergone withdrawal and wish to ...
Emmert Roberts, Elizabeth Sanderson, Thomas Santo Jr., Matthew Hickman, Michael Farrell, Louisa Degenhardt   +5 more
wiley   +1 more source

Factors that impact opioid agonist therapy in Northern and Rural Ontario

, 2016
Opioid agonist therapy is the gold standard of care for opioid dependence. However, the efficacy of treatment may be hindered by concurrent drug use, including cocaine and benzodiazepines.
Franklyn, Alexandra Michelle
core  

Barriers to initiating opioid agonist treatments reported by physicians working in provincial correctional facilities for adults in Ontario, Canada, % of N = 27.

, 2018
*OST = opioid substitution therapy, which includes opioid agonist treatments methadone and buprenorphine/naloxone.
Alexandra Patel (4856797), Lori Kiefer (3157992), Matthew J. To (504576), Leonora Regenstreif (4856794), Fiona G. Kouyoumdjian (489495)   +4 more
core   +1 more source

Beyond abstinence: Redefining success in cannabis use disorder treatment

Addiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin, Frances R. Levin, John Mariani, Christina A. Brezing   +3 more
wiley   +1 more source

Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine

Patient Preference and Adherence, 2018
Mark Gilman,1 Li Li,2 Kerrie Hudson,3 Tara Lumley,2 Georgia Myers,2 Camilla Corte,2 Richard Littlewood2 1Discovering Health, Manchester, UK; 2Applied Strategic, London, UK; 3The Well Communities CIC, Lancaster, UK Purpose: Integrated treatment for ...
Gilman M, Li L, Hudson K, Lumley T, Myers G, Corte C, Littlewood R   +6 more
doaj  

Use of Opioid Agonist Therapy for Medicare Patients in 2013 [PDF]

JAMA Psychiatry, 2016
Anna, Lembke, Jonathan H, Chen
openaire   +2 more sources